The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Pharmacological Research

• Publication date

  2012-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.phrs.2011.11.008PMID 22123497
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury.

  2011cited by this paper
• Overexpression of COX-2 in celecoxib-resistant breast cancer cell lines.

  2010cited by this paper
• CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes.

  2010cited by this paper
• CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model

  2010cited by this paper
• Cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis.

  2009cited by this paper
• Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin.

  2009cited by this paper
• Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon

  2009cited by this paper
• The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation.

  2009cited by this paper
• Reply to the letter to the editor “Long‐term cannabinoid receptor (CB1) blockade in obesity: Implications for the development of colorectal cancer”

  2008cited by this paper
• Rimonabant (SR141716) exerts anti‐proliferative and immunomodulatory effects in human peripheral blood mononuclear cells

  2008cited by this paper
• Cannabinoids in pancreatic cancer: Correlation with survival and pain

  2008cited by this paper
• Long term cannabinoid receptor (CB1) blockade in obesity: Implications for the development of colorectal cancer

  2007cited by this paper
• Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity.

  2007cited by this paper
• Targeting the AKT protein kinase for cancer chemoprevention

  2007cited by this paper
• Anandamide inhibits adhesion and migration of breast cancer cells.

  2006cited by this paper
• The Cannabinoid CB1 Receptor Antagonist Rimonabant (SR141716) Inhibits Human Breast Cancer Cell Proliferation through a Lipid Raft-Mediated Mechanism

  2006cited by this paper
• Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma

  2005cited by this paper
• Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery

  2005cited by this paper
• Activation of the peripheral endocannabinoid system in human obesity.

  2005cited by this paper
• The CB1 receptor antagonist rimonabant reverses the diet‐induced obesity phenotype through the regulation of lipolysis and energy balance

  2005cited by this paper
• Endocannabinoid control of food intake and energy balance

  2005cited by this paper
• NF-κB: linking inflammation and immunity to cancer development and progression

  2005cited by this paper
• The Akt/PKB pathway: molecular target for cancer drug discovery

  2005cited by this paper
• Rimonabant: the first therapeutically relevant cannabinoid antagonist.

  2005cited by this paper
• NF-kappaB: linking inflammation and immunity to cancer development and progression.

  2005cited by this paper
• FoxO: linking new signaling pathways.

  2004cited by this paper
• A new strategy to block tumor growth by inhibiting endocannabinoid inactivation

  2004cited by this paper
• Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis

  2003cited by this paper
• Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice.

  2003cited by this paper
• Mutagenesis and repair by low doses of alpha radiation in mammalian cells.

  2002cited by this paper
• The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

  2002cited by this paper
• The protein kinase B/Akt signalling pathway in human malignancy.

  2002cited by this paper
• Mutagenesis and repair by low doses of α radiation in mammalian cells

  2002cited by this paper
• N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor.

  2002cited by this paper
• The Putative Oncoprotein Bcl-3 Induces Cyclin D1 To Stimulate G1 Transition

  2001cited by this paper
• Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors.

  2001cited by this paper
• Forkhead Transcription Factors Are Critical Effectors of Cell Death and Cell Cycle Arrest Downstream of PTEN

  2000cited by this paper
• Anandamide Induces Apoptosis in Human Cells via Vanilloid Receptors

  2000cited by this paper
• NF-κB Function in Growth Control: Regulation of Cyclin D1 Expression and G0/G1-to-S-Phase Transition

  1999cited by this paper
• Control of apoptosis by Rel/NF-kappaB transcription factors.

  1999cited by this paper
• Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB

  1999cited by this paper
• Control of apoptosis by Rel/NF-κB transcription factors

  1999cited by this paper
• Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor.

  1999cited by this paper
• Aberrant rel/nfkb genes and activity in human cancer

  1999cited by this paper
• Direct control of the Forkhead transcription factor AFX by protein kinase B

  1999cited by this paper
• Appetite suppression and weight loss after the cannabinoid antagonist SR 141716.

  1998cited by this paper
• Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system.

  1998cited by this paper
• Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist.

  1995cited by this paper
• SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

  1994cited by this paper
• Cannabinoid-receptor expression in human leukocytes.

  1993cited by this paper

• Revealing the therapeutic potential of synthetic cannabinoids: a systematic review of cannabinoid receptor binding dynamics and their implications for cancer therapy

  2025cites this paper
• Disorders of cancer metabolism: The therapeutic potential of cannabinoids.

  2022cites this paper
• Inhibition of cannabinoid receptor type 1 sensitizes triple-negative breast cancer cells to ferroptosis via regulating fatty acid metabolism

  2022cites this paper
• Cannabinoid receptors promote chronic intermittent hypoxia-induced breast cancer metastasis via IGF-1R/AKT/GSK-3β

  2021cites this paper
• Transcription Profile and Pathway Analysis of the Endocannabinoid Receptor Inverse Agonist AM630 in the Core and Infiltrative Boundary of Human Glioblastoma Cells

  2021influential citation
• Mangifera indica leaves extract and mangiferin modulate CB1 and PPARγ receptors and others markers associated with obesity

  2019cites this paper
• Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a G&agr;i/o protein inhibitor

  2018influential citation
• Rimonabant Kills Colon Cancer Stem Cells without Inducing Toxicity in Normal Colon Organoids

  2018cites this paper
• Effect of endocannabinoid signalling on cell fate: life, death, differentiation and proliferation of brain cells

  2018cites this paper
• Insights into the effects of the endocannabinoid system in cancer: a review

  2018cites this paper
• INSIGHT ON THE IMPACT OF ENDOCANNABINOID SYSTEM IN CANCER: A REVIEW

  2018cites this paper
• Overexpression of cannabinoid receptor 1 in esophageal squamous cell carcinoma is correlated with metastasis to lymph nodes and distant organs, and poor prognosis

  2017cites this paper
• Valproic acid induces autophagy by suppressing the Akt/mTOR pathway in human prostate cancer cells

  2016cites this paper
• Resveratrol induces apoptosis and alters gene expression in human fibrosarcoma cells.

  2015cites this paper
• Regulation of inflammation and proliferation of human bladder carcinoma cells by type-1 and type-2 cannabinoid receptors.

  2015cites this paper
• Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients' cells

  2015cites this paper
• The dynamic nature of type 1 cannabinoid receptor (CB1) gene transcription

  2012influential citation
• Expression of the cannabinoid type I receptor and prognosis following surgery in colorectal cancer

  2012cites this paper